ANNE-MARIE FREMIN: Open Payments
NPI 1558537001 · HAMMOND, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,046 in 91 payments from 15 companies in 2025. Trend: 2023 $0 · 2024 $1,226 · 2025 $2,046
Food & beverage: $1,993Education: $53
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 23 | $497 |
| AstraZeneca Pharmaceuticals LP | 15 | $444 |
| Regeneron Healthcare Solutions, Inc. | 24 | $373 |
| GENZYME CORPORATION | 7 | $258 |
| Novartis Pharmaceuticals Corporation | 10 | $189 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $56 |
| PFIZER INC. | 2 | $43 |
| Amgen Inc. | 1 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $31 |
| BioCryst US Sales Co., LLC | 1 | $29 |
Products named: DUPIXENT, NUCALA, TEZSPIRE, TRELEGY ELLIPTA, BREZTRI, FASENRA, NEFFY, AIRSUPRA.
Industry payments across LA — which companies pay providers there.
